Lagerstandorte

New Jersey, USA
Czech Republic, EU
Mumbai, India

* Vorbehaltlich Verfügbarkeit

Dokumentation

MSDS herunterladen

Beispiel-COA herunterladen

Enthält: HPLC, MASS/LC-MS, 1H-NMR, FT-IR, Gehalt, Structure Elucidation Report (SER) sowie zusätzliche analytische Daten je nach Produkt.

2715120- 86-6Upadacitinib Bisacyl Impurity

● Auf Lager

Katalog-Nr.::	VE0027853
CAS-Nr.::	2715120- 86-6
Summenformel::	C20H21F6N7O2
Molare Masse::	505.42 g/mol

Angebot anfordern

Zur RFQ-Liste hinzufügen

Zusätzliche Informationen zu CAS 2715120- 86-6

Parent drug

Upadacitinib

IUPAC-Name

8-((3R,4S)-4-ethyl-1-((2,2,2-trifluoroethyl)carbamoyl) pyrrolidin-3-yl)-N-(2,2,2- trifluoroethyl)-3H-imidazo[1,2-a] pyrrolo[2,3-e]pyrazine-3-carboxamide

Pharmacopeial Synonyms

N/A

Synonyme

N/A

SMILES

O=C(N1C=CC2=C1N=CC3=NC=C([C@H]4CN(C(NCC(F)(F)F)=O)C[C@H]4CC)N32)NCC(F)(F)F

InChI

InChI=1S/C20H21F6N7O2/c1-2-11-7-31(17(34)29-9-19(21,22)23)8-12(11)14-5-27-15-6-28-16-13(33(14)15)3-4-32(16)18(35)30-10-20(24,25)26/h3-6,11-12H,2,7-10H2,1H3,(H,29,34)(H,30,35)/t11-,12+/m1/s1

Beschreibung

Upadacitinib Bisacyl Impurity (CAS 2715120-86-6) is a process-related degradant detected during upadacitinib synthesis and stability testing. Analytical characterization by LC-MS, HPLC and NMR confirms the bisacyl structural motif and mass shift indicative of acylation of the parent scaffold. Left uncontrolled, this impurity can affect API purity and stability, so validated quantitation methods with MS confirmation and forced-degradation studies are recommended for reliable impurity profiling. Control measures typically target acylation step optimization, purification parameter adjustment and specification setting in line with ICH Q3A/B thresholds, with reporting of retention time, exact mass and fragmentation pattern.